Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Dornase alfa - Genentech

Next Previous
Drug Profile

Dornase alfa - Genentech

Alternative Names: DNase; Dornase alpha; dornase-alpha; Pulmozyme; Recombinant human deoxyribonuclease I; rhDNase

Latest Information Update: 05 Nov 2023

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Genentech
  • Developer Chugai Pharmaceutical; Genentech; University of Illinois at Chicago
  • Class Antifibrotics; Enzymes; Eye disorder therapies; Recombinant proteins
  • Mechanism of Action Deoxyribonuclease I stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Cystic fibrosis
  • New Molecular Entity No

Highest Development Phases

  • Marketed Cystic fibrosis
  • Phase I/II Dry eyes; Graft-versus-host disease
  • Discontinued Chronic obstructive pulmonary disease; COVID 2019 infections; Lupus nephritis

Most Recent Events

  • 10 Jan 2022 Discontinued - Phase-II for COVID-2019 infections (Combination therapy) in USA (Inhalation) as per Data Monitoring Committee recommendation
  • 10 Jan 2022 Efficacy and safety data from phase II I-SPY COVID trial in COVID-2019 infections released by Quantum Leap Healthcare
  • 08 Apr 2021 Dornase alfa is still in phase I/II trials for Graft-Vs-Host Disease in USA (Ophthalmic, drops) (NCT02702518)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top